Description: Alzamend Neuro, Inc., a preclinical stage biopharmaceutical company, focuses on developing products for the treatment of neurodegenerative diseases and psychiatric disorders. The company's lead product candidate is AL001 for the treatment of Alzheimer's and other neurodegenerative diseases and psychiatric disorders. It is also developing AL002, a cell-based therapeutic vaccine, which seeks to restore the ability of the patient's immunological system to Alzheimer's. The company was incorporated in 2016 and is headquartered in Tampa, Florida.
Home Page: www.alzamend.com
ALZN Technical Analysis
3500 Lenox Road NE
Atlanta,
GA
30326
United States
Phone:
844 722 6333
Officers
| Name | Title |
|---|---|
| Mr. Stephan Jackman | CEO & Director |
| Mr. Kenneth S. Cragun CPA | Sr. VP of Fin. |
| Mr. David J. Katzoff | Chief Financial Officer |
| Mr. Henry C. W. Nisser Esq. | Exec. VP, Gen. Counsel & Director |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 11.6318 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | 2021-06-15 |
| Fiscal Year End: | April |
| Full Time Employees: | 4 |